John B.A.G. Haanen

Research interests

Publications

• Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma

  New England Journal of Medicine · 2024 · https://doi.org/10.1056/nejmoa2407417

• Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

  Zurich Open Repository and Archive (University of Zurich) · 2022 · https://doi.org/10.5167/uzh-213514

• Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

  Annals of Oncology · 2022 · https://doi.org/10.1016/j.annonc.2022.10.001

• Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers

  Nature Medicine · 2020 · https://doi.org/10.1038/s41591-020-0805-8

• Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

  New England Journal of Medicine · 2019 · 10.1056/nejmoa1816047

• Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1904059

• Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1910836

• Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

  Nature Medicine · 2019 · 10.1038/s41591-019-0432-4

• Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma

  Nature Medicine · 2018 · 10.1038/s41591-018-0198-0

• Generation of Tumor-Reactive T Cells by Co-culture of Peripheral Blood Lymphocytes and Tumor Organoids

  Cell · 2018 · 10.1016/j.cell.2018.07.009

• Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma

  Cell · 2018 · 10.1016/j.cell.2018.11.043

• Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2017 · 10.1093/annonc/mdx225

• Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

  Annals of Oncology · 2017 · 10.1093/annonc/mdx176

• Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1709684

• The “cancer immunogram”

  Science · 2016 · 10.1126/science.aaf2834

• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

  New England Journal of Medicine · 2015 · https://doi.org/10.1056/nejmoa1504030

• Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

  The Lancet · 2015 · 10.1016/s0140-6736(15)60898-4

• Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

  The Lancet Oncology · 2014 · 10.1016/s1470-2045(14)70012-9

• Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma

  Nature · 2014 · 10.1038/nature13121

• Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma

  Nature Communications · 2014 · 10.1038/ncomms6712

• High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma

  Nature Medicine · 2014 · 10.1038/nm.3773

• Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

  New England Journal of Medicine · 2014 · 10.1056/nejmoa1406037

• Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma

  Journal of Clinical Oncology · 2013 · 10.1200/jco.2012.47.7521

• Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

  Journal of Clinical Oncology · 2013 · 10.1200/jco.2012.44.6112

• Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

  New England Journal of Medicine · 2011 · https://doi.org/10.1056/nejmoa1103782

• Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

  New England Journal of Medicine · 2010 · https://doi.org/10.1056/nejmoa1003466

• Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression.

  The Journal of Experimental Medicine · 1991 · 10.1084/jem.174.4.915

Current projects

No projects listed.